1）Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert JM. Antibodies to watch in 2024. MAbs 2024; 16: 2297450. 2）Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158-68. 3）Takeuchi T, Chino Y, Kawanishi M, Nakanishi M, Watase H, Mano Y, et al. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Res Ther 2023; 25: 60. 4）Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, et al. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials. Lancet Rheumatol 2024; 6: e226-e236. 5）Fukudo M, Sasaki T, Ohsaki Y. PD-1 blockers: Staying long in the body and delayed toxicity risks. J Thorac Oncol 2020; 15: e42-e44. 6）Fukudo M, Mishima K, Kimura N, Shinden Y, Sasaki T, Okumura S, et al. Long-term follow-up of pharmacokinetics (PK) and immunogenicity of the anti–PD-1 antibodies nivolumab (Nivo) and pembrolizumab (Pembro) in real-world practice. J Clin Oncol 2019; 37: suppl.3120. 7）Gorelik Y, Freilich S, Gerassy-Vainberg S, Pressman S, Friss C, Blatt A, et al. Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN. Gut 2022; 71: 287-95. 8）Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol 2019; 5: 1774-8. 9）Eng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y, et al. Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: A population-based study. J Clin Oncol 2023; 41: 3122-34.抗体医薬品のPK-ADA解析を基盤とした治療最適化に資するリアルワールドエビデンスの創出文 献10）Zhu Y, Wang Q, Frederick B, Bouman-Thio E, Marini JC, Keen M, et al. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies. Clin Drug Investig 2013; 33: 291-301.11）Guo Y, Remaily BC, Thomas J, Kim K, Kulp SK, Mace TA, et al. Antibody drug clearance: An underexplored marker of outcomes with checkpoint inhibitors. Clin Cancer Res 2024; 30: 942-58.12）Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16: 626-38.13）Le Bastard Q, Al-Ghalith GA, Grégoire M, Chapelet G, Javaudin F, Dailly E, et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther 2018; 47: 332-45.14）Hirayama H, Morita Y, Imai T, Takahashi K, Yoshida A, Bamba S, et al. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease. BMC Gastroenterol 2022; 22: 195.15）Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease. Gastroenterology 2018; 154: 1660-71.16）Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2020; 18: 2244-55.17）Porth R, Deyhim T, Geeganage G, Smith B, Zullow S, Rabinowitz LG, et al. Proactive therapeutic drug monitoring of ustekinumab is associated with increased drug persistence in patients with inflammatory bowel disease. Inflamm Bowel Dis 2024, doi: 10.1093/ibd/izae231. Online ahead of print.11
元のページ ../index.html#25